aTyr Pharma, Inc. (ATYR)
3.82
+0.13
(+3.52%)
USD |
NASDAQ |
Nov 20, 16:00
3.80
-0.02
(-0.52%)
After-Hours: 20:00
aTyr Pharma Debt to Equity Ratio : 0.3213 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.3213 |
| June 30, 2026 | 0.2316 |
| March 31, 2026 | 0.202 |
| December 31, 2025 | 0.1783 |
| September 30, 2025 | 0.154 |
| June 30, 2025 | 0.1694 |
| March 31, 2025 | 0.1731 |
| December 31, 2024 | 0.1897 |
| September 30, 2024 | 0.2077 |
| June 30, 2024 | 0.1697 |
| March 31, 2024 | 0.1672 |
| December 31, 2023 | 0.1665 |
| September 30, 2023 | 0.1547 |
| June 30, 2023 | 0.1449 |
| March 31, 2023 | 0.13 |
| December 31, 2022 | 0.1614 |
| September 30, 2022 | 0.1121 |
| June 30, 2022 | 0.0147 |
| March 31, 2022 | 0.0116 |
| December 31, 2021 | 0.0126 |
| September 30, 2021 | 0.0137 |
| June 30, 2021 | 0.0445 |
| March 31, 2021 | 0.0409 |
| December 31, 2020 | 0.0707 |
| Date | Value |
|---|---|
| September 30, 2020 | 0.171 |
| June 30, 2020 | 0.2107 |
| March 31, 2020 | 0.2298 |
| December 31, 2019 | 0.5537 |
| September 30, 2019 | 0.5144 |
| June 30, 2019 | 0.5212 |
| March 31, 2019 | 0.6012 |
| December 31, 2018 | 0.4764 |
| September 30, 2018 | 0.4568 |
| June 30, 2018 | 0.4312 |
| March 31, 2018 | 0.3666 |
| December 31, 2017 | 0.3071 |
| September 30, 2017 | 0.204 |
| June 30, 2017 | 0.3642 |
| March 31, 2017 | 0.1888 |
| December 31, 2016 | 0.1519 |
| September 30, 2016 | 0.0357 |
| June 30, 2016 | 0.0403 |
| March 31, 2016 | 0.043 |
| December 31, 2015 | 0.0447 |
| September 30, 2015 | 0.046 |
| June 30, 2015 | 0.0483 |
| March 31, 2015 | 0.2197 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0518 |
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Anika Therapeutics, Inc. | 0.1901 |
| Savara, Inc. | 0.2815 |
| Arrowhead Pharmaceuticals, Inc. | 27.84 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 59.81M |
| Total Liabilities (Quarterly) | 26.01M |
| Shareholders Equity (Quarterly) | 33.98M |
| Current Ratio | 3.047 |
| Net Debt Paydown Yield | 1.16% |